Mitotane 米托坦; 2,4′-DDD; o,p'-DDD|cas:53-19-0|西域试剂

Mitotane 米托坦; 2,4′-DDD; o,p'-DDD,99.92%

产品编号：Bellancom-13690| CAS NO：53-19-0| 分子式：C₁₄H₁₀Cl₄| 分子量：320.04

Mitotane(2,4′-DDD)是DDD的同分异构体和DDT的衍生物，有抗癌活性，可作用于肾上腺皮质癌。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-13690		￥512.00	杭州北京（现货）
Bellancom-13690		￥837.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Mitotane 米托坦; 2,4′-DDD; o,p'-DDD

产品介绍

Mitotane (2,4’-DDD) 是 DDD 的同分异构体和 DDT 的衍生物，有抗癌活性，可用于研究肾上腺皮质癌。Mitotane 的肾上腺皮质溶解作用至少部分是通过细胞内游离胆固醇 (FC) 积累引起的脂毒性。Mitotane 可对促皮质激素细胞产生直接垂体作用。Mitotane 可通过类固醇和外源性受体 (SXR) 激活诱导 CYP3A4 基因表达，并存在活性分子-活性分子相互作用。

生物活性

Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions^[4].

体外研究

Mitotane (1 nM-100 μM; 6 days) significantly reduces H295R cell proliferation.
Mitotane (10-100 μM; 6 or 48 h; TαT1 cells) reduces TαT1 cell viability in time- and dose-dependent manners; significantly and dose dependently increases caspase 3/7 activity from 60 μM to 80 μM; induced a significant and dose-dependent reduction in TSH secretion and TSH β-subunit mRNA expression from 40 μM to 100 μM.
Mitotane (1-30 μM; 24 h; HepG2) increases transcription of the CYP3A4 and CYP2B6 gene in a dose-dependent manner.
Mitotane (20 and 40 μM; 6 h) significantly reduces the number of neutral lipid droplets per cell in HepaRG, also induces a significant decrease in triacylglycerol-labeled lipid droplets; decreases the expression levels of PLIN1 and PLIN3^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	H295R cells
Concentration:	1 nM-100 μM
Incubation Time:	6 days
Result:	Significantly reduced H295R cell proliferation with an IC₅₀ of 22.8 μM.

Cell Viability Assay

Cell Line:	TαT1 cells
Concentration:	10, 40, 60, 80 and 100 μM
Incubation Time:	6 or 48 h
Result:	Did not modify cell viability at 10-80 μM, while significantly (P < 0.01) reduced cell viability (-56%) at 100 μM, after 6 h incubation. Did not modify cell viability at 10-60 μM, whereas cell viability was significantly reduced at 60 μM (-31%; P < 0.05), 80 μM (-53%; P < 0.01), and 100 μM (-75.5%; P < 0.01), after 48 h incubation.

RT-PCR

Cell Line:	HepaRG cells and human hepatocytes
Concentration:	0.1, 1, 10, 20, 30, or 40 μM
Incubation Time:	24 or 48 h
Result:	Increased mRNA levels of CYP3A4 and CYP2B6.

Western Blot Analysis^[4]

Cell Line:	H295R
Concentration:	20, 40 and 50 μM
Incubation Time:	6 h
Result:	Decreased the expression levels of PLIN1 and PLIN3.

体内研究
(In Vivo)

Mitotane (440 mg/kg; i.p. or p.o,; 5 days a week, for 7 weeks) significantly reduces the volume of xenografts at an early time point after H295R cells inoculation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/SCID/γ_c^null mice (4-week-old; inoculated subcutaneously 6 × 10⁶ H295R cells into the right flank)
Dosage:	440 mg/kg
Administration:	i.p. or p.o,; 5 days a week, for 7 weeks
Result:	Significantly reduced the volume of xenografts at an early time point (day 13) after H295R cells inoculation. The effect of oral mitotane treatment became non-significant by day 20 after H295R cells inoculation, while the effect of i.p. mitotane lasted until day 34.

体内研究

Mitotane (440 mg/kg; i.p. or p.o,; 5 days a week, for 7 weeks) significantly reduces the volume of xenografts at an early time point after H295R cells inoculation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/SCID/γ_c^null mice (4-week-old; inoculated subcutaneously 6 × 10⁶ H295R cells into the right flank)
Dosage:	440 mg/kg
Administration:	i.p. or p.o,; 5 days a week, for 7 weeks
Result:	Significantly reduced the volume of xenografts at an early time point (day 13) after H295R cells inoculation. The effect of oral mitotane treatment became non-significant by day 20 after H295R cells inoculation, while the effect of i.p. mitotane lasted until day 34.

体内研究

Mitotane (440 mg/kg; i.p. or p.o,; 5 days a week, for 7 weeks) significantly reduces the volume of xenografts at an early time point after H295R cells inoculation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/SCID/γ_c^null mice (4-week-old; inoculated subcutaneously 6 × 10⁶ H295R cells into the right flank)
Dosage:	440 mg/kg
Administration:	i.p. or p.o,; 5 days a week, for 7 weeks
Result:	Significantly reduced the volume of xenografts at an early time point (day 13) after H295R cells inoculation. The effect of oral mitotane treatment became non-significant by day 20 after H295R cells inoculation, while the effect of i.p. mitotane lasted until day 34.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (312.46 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.1246 mL	15.6230 mL	31.2461 mL
5 mM	0.6249 mL	3.1246 mL	6.2492 mL
10 mM	0.3125 mL	1.5623 mL	3.1246 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (7.81 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.81 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (7.81 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (7.81 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.81 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.81 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在西域网站选购。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

. Doghman M, et al. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma. Mol Cell Endocrinol. 2013 Dec 5;381(1-2):66-9. [Content Brief]

. Zatelli MC, et al. Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology. 2010 Jun;151(6):2453-61. [Content Brief]

. Takeshita A, Igarashi-Migitaka J, Koibuchi N, Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor. J Endocrinol. 2013 Feb 15;216(3):297-305. [Content Brief]

[4]. Warde KM, et al. Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma. Endocrinology. 2022 Sep 1;163(9):bqac102. [Content Brief]

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

产品编号(Item Number)

批号(Lot Number)

符号	GHS08
信号词	Warning
危害声明	H351
警示性声明	P280
个人防护装备	dust mask type N95 (US);Eyeshields;Gloves
危害码 (欧洲)	Xn:Harmful
风险声明 (欧洲)	R40
安全声明 (欧洲)	S36/37
危险品运输编码	3249
WGK德国	3
RTECS号	KH7880000
包装等级	III
危险类别	6.1(b)
海关编码	2903999090

1. 物质的识别

产品名：	Mitotane
CAS号：	53-19-0
制造商/供应商：	西域试剂网站：www.hzbp.cn 邮件：13911702513@139.com

2. 合成/成分数据

产品名：	Mitotane
别名：	2,4′-DDD; o,p'-DDD
分子式：	C14H10Cl4
分子量：	320.04

3. 急救措施

吸入后：	如果吸入，移至空气新鲜处，如果呼吸困难，给输氧，如呼吸停止，给予人工呼吸。
皮肤接触后：	用大量的水冲洗，移除污染的衣服和鞋子。
眼睛接触后：	检查并取下隐形眼镜，并用大量的水冲洗；呼叫医生。
吞食后：	如果吞食，用大量纯净水漱口；呼叫医生。

4. 消防措施

适当的灭火剂：	雾状水，二氧化碳，干粉或泡沫。
防护设备：	穿戴自给式呼吸器和防护服，以防止与皮肤和眼睛接触。

5. 泄漏应急处理

安全防范措施：	封锁泄漏区域；穿戴自给式呼吸器，防护服和厚橡胶手套。
清洁/收集措施：	使用液体粘合原料（硅藻土，通用粘合剂）吸取精细粉末；使用酒精擦洗表面和设备除去污渍；根据第11条处理被污染的材料。

6. 处理和储存

安全处理说明：	避免吸入和接触皮肤，眼睛及衣物；材料可能略微具有刺激性。
储存：	粉末型式 -20°C 3年；4°C 2年溶于溶剂 -80°C 6个月；-20°C 1个月

7. 接触控制和个人防护

呼吸设备：	NIOSH / MSHA认可的呼吸器。
双手保护：	耐化学腐蚀的橡胶手套。
眼睛防护：	化学安全护目镜。

8. 稳定性和反应活性

稳定性：	按照说明存储是稳定的；避免强氧化剂。
热分解/其他要避免的情况：	避免光和热。

9. 毒性资料

急性毒性：	无可用资料。
主要刺激性影响：	无可用资料。
在皮肤上：	无可用资料。
对眼睛：	无可用资料；可能具有刺激性。

10. 生态资料

一般注意事项：

无可用资料。

11. 废弃处置

按照所在国家，省份，县市和地方的法规处置。

12. 运输信息

正确的运输名称：	无
非危险品运输：	这种物质被视为非危险品运输。

13. 法规信息

尚未有针对此产品作出的化学安全性评估。

14. 其他信息

上游产品 8
789-02-6 27683-60-9 108-90-7 36692-27-0
50-29-3 10291-39-1 89-98-5 7664-93-9
下游产品 6
85-29-0 14835-94-0 77008-62-9 90284-72-3
39274-24-3 52094-02-7